This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ASCO GU 2017
Press Releases
Prostate Cancer
Kidney Cancer
Penile, Urethral & Testicular Cancer
Bladder Cancer
Highlights from ASCO GU 2017
Viewing 78-97 of 100 articles
ASCO GU 2017: Challenging Cases in High-Risk, Recurrent, and Advanced Prostate Cancer (ARS) - Radiation Oncologist - Session Highlights
ASCO GU 2017: Challenging Cases in High-Risk, Recurrent, and Advanced Prostate Cancer (ARS) - Medical Oncologist - Session Highlights
ASCO GU 2017: Challenging Cases in High-Risk, Recurrent, and Advanced Prostate Cancer (ARS) - Surgeon - Session Highlights
ASCO GU 2017: Keynote Lecture: Immunology of Prostate Cancer - Session Highlights
ASCO GU 2017: Clinical significance of AR mRNA quantification from circulating tumor cells in men with metastatic castrate resistant prostate cancer treated with abiraterone or enzalutamide - Session Highlights
ASCO GU 2017: Evaluation of the Decipher prostate cancer classifier to predict metastasis and disease-specific mortality from genomic analysis of diagnostic prostate needle biopsy specimens - Session Highlights
ASCO GU 2017: Luminal and basal subtyping of prostate cancer. - Session Highlights
ASCO GU 2017: Advances in the Understanding and Treatment of Androgen-Receptor-Indifferent Prostate Cancer - Session Highlights
ASCO GU 2017: Adjuvant androgen deprivation (ADT) versus mitoxantrone plus prednisone (MP) plus ADT in high-risk prostate cancer (PCa) patients following radical prostatectomy: A phase III intergroup trial (SWOG S9921) NCT00004124. - Session Highlights
ASCO GU 2017: The long tail of significantly mutated genes in prostate cancer - Session Highlights
ASCO GU 2017: Genomic Evolution in Primary and Therapy-Resistant Prostate Cancer - Session Highlights
ASCO GU 2017: Using Liquid Biopsies to Interrogate Circulating Tumor Clone Dynamics and Prostate - Session Highlights
ASCO GU 2017: Prostate cancer meta-analysis from more than 145,000 men to identify 65 novel prostate cancer susceptibility loci - Session Highlights
ASCO GU 2017: Active Surveillance Patient Perspective Question and Answer Panel - Session Highlights
ASCO GU 2017: Genomic Tests in Active Surveillance and the Role of Hereditary Testing - Session Highlights
ASCO GU 2017: Imaging To Guide Active Surveillance - Session Highlights
ASCO GU 2017: What ProtecT Tells Us About Active Surveillance - Session Highlights
ASCO GU 2017: Canadian Vs. U.S. Guidelines on Active Surveillance - Session Highlights
ASCO GU 2017: Welcome Address to the Genitourinary Cancer Symposium 2017 - Session Highlights
ASCO GU 2017: Some Patients Experience Long-Term Tumor Control Even After Stopping Immunotherapy Early
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free